

pBOOST3-mcs

Negative control plasmid for the pBOOST3 vaccine adjuvant plasmid

Catalog # pbst3-mcs

For research use only

Version 20K16-MM

PRODUCT INFORMATION

Content:

- 20 µg of lyophilized pBOOST3-mcs plasmid
- 1 ml of Zeocin™ (100 mg/ml)

Shipping and storage:

Products are shipped at room temperature.

Lyophilized DNA is stable for 12 months when stored at -20°C.

Resuspended DNA is stable for 6 months when stored at -20°C. Avoid repeated freeze-thaw cycles.

Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing.

Plasmid DNA was purified by ion exchange chromatography and lyophilized.

- **Ori pMB1** is a minimal *E. coli* origin of replication with the same activity as the longer Ori.

- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

- **Sh ble**: The *Sh ble* gene from *Streptallocteichus hindustanus* encodes a small protein that confers resistance to Zeocin™ by binding to the antibiotic.

References:

1. Ishii KJ. *et al.*, 2008. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. *Nature*. 451:725-729.
2. Robinson HL., 1999. DNA vaccines: basic mechanism and immune responses (Review). *Int J Mol Med*. 4(5):549-55.
3. Takeshita F. *et al.*, 2006. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. *J. Virol*. 80:6218-6224.
4. Kim, D.W. *et al.*, 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. *Gene* 2: 217-223.
5. Takebe, Y. *et al.*, 1988. R alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol. Cell Biol*. 1: 466-472.

GENERAL PRODUCT USE

The pBOOST3-mcs plasmid is a negative control plasmid for use with pBOOST3-mTBK1. The pBOOST3-mTBK1 plasmid was developed as a genetic adjuvant for DNA vaccines to potentiate the immune response to a specific antigen. The pBOOST3-mTBK1 plasmid contains the mouse TANK-binding kinase 1 (mTBK1) gene. TBK1, a non-canonical IκB kinase, was shown to mediate the adjuvant effect of DNA vaccines¹. Administration of DNA vaccines induces the production of type I interferons and inflammatory cytokines in a CpG-independent manner but in TBK1-dependent manner¹.

The method of plasmid DNA vaccine delivery is known to bias the immune response to a specific antigen towards a type 1 (T-cell) response². A DNA vaccine incorporated with genetic adjuvant such as the MyD88 or the TRIF gene has been shown to enhance immune responses³. As TBK1 has been shown to play a crucial role in humoral responses, coadministration of a TBK1-expressing plasmid is expected to further boost DNA vaccine-induced immunogenicity.

PLASMID FEATURES

- **hEF1 / HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter⁴ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat⁵. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **SV40 pAn**: The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



 InvivoGen

EagI (2) **EcoRI (19)** **EcoO109I (30)**
NotI (2) **XbaI (15)** **Sdai (29)**

Asp718I (66)
Acc65I (66)

PvuII (92)

1 GCGGCCGCTATGCATCTAGAATTCTCGAGGGCTGAAATAACCTCTGAAAGAGGAACCTGGTAGGTACCTCTGAGGCGGAAAGAACCCAGCTGTGGAA

101 TGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCAGCAGGAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCC

201 CCAGGCTCCCCAGCAGGAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGTCTGAGGCGCACATGCCACAGT
SphI (164) SpeI (266)

301 CCCCAGAGAAGTGGGGGAGGGTGGCAATTGAACGGGTGCTAGAGAAGGTGGCGGGTAAACTGGAAAGTGATGCGTGTACTGGCTCCGCTT

EcoNI (346)
Psp1406I (450)
HindIII (491)
PvuII (487)

401 TTTCGGAGGGTGGGGAGAACGTAATAAGTGCAGTAGTCGGCTGAACGTTCTTCGCAACGGTTTGCGCCAGAACACAGCTGAAGCTTCAG

Bsu36I (538)
EcoNI (537)

501 GGGCTCGCATCTCCTCACGCGCCCGCGCCATCCACGCCGTTGAGTCGGCTCTGCCGCTCCGCCGTGGTGCTCCT

601 AACCTCGTCCGCCGTAGGTAAGTTAAAGTCAGGTCAGACCGGGCTTGTCCGGCTCCCTGGAGCCTACCTAGACTCAGCCGGCTCTCCACG

KasI (781) **SgrAI (798)**

701 CTTTGCCTGACCCCTGCTTGTCAACTCTACGTCTTGTCTGCGCCGTTACAGATCCAAGCTGTGACCGCGCTACCTGAGATCacc

Eco47III (820) **NheI (836)**
BamHI (812) **XcmI (837)**
SalI (806) **AfeI (820)** **NcoI (830)** **MscI (844)**

801 ggctgtcgacggatccaggcgtctgcagCCATGGCTAGCTGGCAGACATGATAAGATACTTGTGAGTTGGACAAACCAACTAGAATGCAGTG

HpaI (976)

901 AAAAAAATGCTTATTGTGAAATTGTGATGCTATTGCTTATTGTAACCATTATAAGCTGCAATAAACAGTTAACACAACAATTGCATTCAATT

AseI (1073)
XmnI (1069)

1001 ATGTTTCAGGTTCAAGGGGAGGTGGAGGTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGAAATTACTCTAAACATAGCATTGCAAAAC

1101 TTTAACCTCAAATCAAGCCTACTTGAATCCCTCTGAGGGATGAAAGGCATAGGCATAGGCATAGGCATAGGCATAGGCATAGGCATAGGCAGC

1201 CTCACCTCTTCATGGAGTTAAGATATAGTGTATTCCCAGGTTGAACACTAGCTCTCAATTCTTATGTTAAATGCACTGACCTCCACATTG

SspI (1315) **Swal (1330)** **EcoO109I (1389)**

1301 CCTTTTTAGAAAATTCAGAAATAATTAAATACATTGCAATGAAAATAATGTTTTATTAGGCAGATCCAGATGCTCAAGGCCCTCATAA

1401 TATCCCCAGTTAGTAGTGTGGACTTAGGAACAAAGGAACCTTAAATAGAAAATGGACAGCAAGAACGGAGCTCTAGCTTATCCTCAGTCTGCTCC

125 • D Q E

ApaLI (1512)
DraIII (1511) **EagI (1526)**

1501 TCTGCCACAAAGTGCACGAGTTGGCGGGGGTGCAGGGCGAACCTCCGCCCCACGGCTGCTGCCATCTGGTATGCCGGCCGGAGGCGT
 120 E A V F H V C N G A P D R L A F R G W P Q E G I E T M A P G S A D

1601 CCCGAAGTTCTGGACACGACCTCCGACACTCGGCTACAGCTCGCCAGGCCACACCCAGGCCAGGGTGTGTCGGCACCCACTGGT
 87 R F N T S V V E S W E A Y L E D L G R V W V W A L T N D P V V Q D

SgrAI (1743) **XmaI (1769)**

1701 CTGGACCGCGCTGATGAAACAGGGTACGTCGTCGGACACACCGCGAACGTCGCTCCACGAAGTCCGGAGAACCCAGCCAGGGTGTGTCGGCACCCACTGGT

54 Q V A S I F L T V D D R V V G A F D D E V F D R S F G L R D T W F

AtII (1819)

BsrBI (1810) **BssHII (1821)** **MscI (1858)**

1801 TCGACCGCTCCGGCGAGTCGCGCGGGTGGACACGGAACGGACTGGTCACTGGCCATGATGGCTCCTCgtcaggagaggaaagagaaggt

20 E V A G A V D R A T L V P V A S T L K A M

Asel (1957) **PacI (1986)** **BspLU1II (1992)**

1901 tagtacaattgCTATAGTGTATTACTATGCAAGATATACTATGCCAATGATTAACTGGTCAAATAGGGCTGCAGGTTAAATTAGAATGAGTGTAG

2001 CAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCGTTGCTGGCTTCTCCATAGGCCTCCGCCCTGACGAGCATCACAAATCGACGCTC

2101 AAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGGCTTCTCCCTGGAGCTCCCTCGTGCCTCTCTGTTCCGACCCCTGGCTTAC

2201 GGATACCTGTCCGCTTCTCCCTGGGAAGCGTGGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTGGTAGGTCTGGCTTCCGACCTGGCTTAC

ApaLI (2306)

2301 GCTGTGTCACGAACCCCCCGTTCAGCCGACCGCTGCGCTTATCCGTAACATCGTCTGAGTCCAACCCGTAAGACACGACTTATGCCACTGGC

2401 AGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGGCTACAGAGTTCTGAAGTGGTGGCTAACTACGGTACACTAGAAGAACAGTA

2501 TTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGAAACAAACCACCGCTGGTAGCGGTGGTTTTTG
2601 TTTGCAAGCAGCAGATTACCGCGAGAAAAAAGGATCTCAAGAAGATCCTTGATCTTCTACGGGGCTGACGCTCAGTGGAACGAAAACTCACGTTA
2701 AGGGATTTGGTCATGGCTAGTTAATTAA_{CATTTAAATCA}

PacI (2726) Swal (2734)
